BHVN Description — Biohaven Pharmaceutical Holding Co Ltd
Biohaven Pharmaceutical is a clinical-stage biopharmaceutical company with a portfolio of late-stage product candidates targeting central nervous system diseases. Co.'s product candidates are small molecules and based on three mechanistic platforms-calcitonin gene-related peptide (CGRP) receptor antagonists, glutamate modulators, and myeloperoxidase inhibitors. Co. is developing rimegepant as an orally available, selective and small molecule CGRP receptor antagonist for the acute and preventive treatment of migraine. Co. is developing troriluzole and BHV-0223, acting as glutamate transporter modulators, while BHV-5000 is an antagonist of the glutamate N-methyl-D-aspartate receptor.